Paper Details

  1. Home
  2. Paper Details

Characterization of the MYB-inhibitory potential of the Pan-HDAC inhibitor LAQ824.

Author: KlempnauerKarl-Heinz, YusenkoMaria V

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

MYB is a transcription factor implicated in the development of acute myeloid leukemia (AML). This study investigated the MYB-inhibitory potential of LAQ824, an HDAC inhibitor. LAQ824 and related inhibitors were found to degrade MYB and inhibit its activity in AML cells, leading to myeloid differentiation and cell death. These findings suggest that LAQ824 and related HDAC inhibitors may have therapeutic potential in AML.
Paper Details　
Original Abstract of the Article :
A large body of work has shown that MYB acts as a master transcription regulator in hematopoietic cells and has pinpointed MYB as a potential drug target for acute myeloid leukemia (AML). Here, we have examined the MYB-inhibitory potential of the HDAC inhibitor LAQ824, which was identified in a scre...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10074929/

データ提供：米国国立医学図書館（NLM）

Exploring LAQ824 as a Potential MYB Inhibitor for Acute Myeloid Leukemia

The battle against acute myeloid leukemia (AML) is a long and arduous journey across the vast desert of cancer research. This study delves into the potential of LAQ824, a pan-HDAC inhibitor, as a novel treatment strategy for AML. The researchers focused on the role of MYB, a master transcription regulator in hematopoietic cells, and investigated whether LAQ824 could inhibit its activity, potentially leading to a new therapeutic approach for AML.

Uncovering the Potential of LAQ824

This research, like a thirsty traveler finding a hidden oasis, unveils the potential of LAQ824 in the fight against AML. Their findings demonstrate that LAQ824 effectively inhibits MYB function, both by inducing its degradation and by directly inhibiting its activity. This dual-pronged approach offers a promising strategy for disrupting the growth and spread of AML cells.

Navigating the Desert of AML Treatment

This study sheds light on the potential of LAQ824 in the treatment of AML, offering a new path forward for patients battling this disease. By inhibiting MYB activity, LAQ824 may help to promote myeloid differentiation and ultimately lead to cell death, potentially offering a new weapon in the fight against AML. Further research is crucial to explore the full potential of LAQ824 in the clinical setting.

Dr. Camel's Conclusion

The desert of AML research is vast and unforgiving, but this study provides a valuable oasis of hope. By exploring the potential of LAQ824, we can navigate this challenging terrain and offer new hope for AML patients.

Date :
  1. Date Completed n.d.
  2. Date Revised 2023-04-22
Further Info :

Pubmed ID

37082582

DOI: Digital Object Identifier

PMC10074929

Related Literature

Article Analysis
・Effects of panobinostat
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.